secwatch.observer — SEC 8-K summary
======================================

Issuer:     Amneal Pharmaceuticals, Inc. (AMRX)
CIK:        0001723128
Form:       8-K
Filed at:   2025-08-05T23:59:59+00:00
Accession:  0001723128-25-000037
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Amneal Q2: rev $725M (+3%), adj EBITDA $184M (+13%), raises FY25 guidance, refi debt
--------------------------------------------------------------------------------

- Q2 net revenue $725M, up 3% YoY; GAAP net income $22M vs $6M in Q2 2024.
- Adjusted EBITDA $184M (+13%); adjusted diluted EPS $0.25 (+56% from $0.16).
- Specialty revenue +23% driven by CREXONT, RYTARY, UNITHROID; Affordable Medicines +1%.
- Raising full-year 2025 guidance; completed oversubscribed debt refinancing extending maturities to 2032.
- FDA approved Brekiya autoinjector for migraine; strong CREXONT Parkinson's uptake.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1723128/000172312825000037/0001723128-25-000037-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1723128/000172312825000037/amrx-20250805.htm
  HTML page:      https://secwatch.observer/filing/0001723128-25-000037

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer